Dr Alvin Kamili is a senior research officer and preclinical scientist in the ZERO Personalised Medicine Program at the Children’s Cancer Institute, Sydney, Australia. He mainly focuses on the establishment of preclinical models for neuroblastoma, a disease in which patients frequently relapse with incurable, drug resistant disease, resulting in long-term survival rates below 50%. His works aim to implement personalised medicine approach to improve patient survival rates through identifying molecular aberration underlying cancer progression in individual patient, screening ex vivo tumour cells against library of anticancer drugs, and developing improved pre-clinical testing models.